Monday's Late Winners & Losers

Among the many downward trending stocks after the closing bell on Monday was Genentech (DNA), even though the biotech company posted a better-than-expected quarterly profit.

The California-based firm said fourth-quarter income came to $737 million on a non-GAAP basis, or 69 cents a share -- up 11.8% from a year earlier. That also comes in 2 cents per share above the average analyst estimate from Thomson Financial. Operating revenue added 9.4% to $2.97 billion, which just tops consensus.

Still, sales for lead drugs Rituxan and Avastan -- $2.28 billion and $1.28 billion, respectively -- were a hair below targets. Genentech shares were falling $1.14, or 1.6%, to $69.50 in recent after hours trading.

Coldwater Creek (CWTR), meanwhile, took a dive after sliding store traffic forced down its fourth-quarter guidance. The Sandpoint, Idaho women's apparel retailer now anticipates losing between 16 cents and 20 cents a share, whereas it had previously expected to break even. Analysts, too, are looking for breakeven per share, excluding items.

Same store sales should sink to the mid- to high-teens compared with last year, and traffic is expected to dwindle in the high single digits. Shares were plummeting 15.5% to $4.35.

Also falling on slashed guidance was Fair Isaac (FIC), a credit-scoring software developer. Shares dropped 9.7% to $25.60 after the Minneapolis outfit pegged fiscal first-quarter earnings at between 37 cents to 39 cents a share, down at least 6 cents from the prior GAAP-based outlook. Revenue expectations were pulled down at least $5 million to between $198 million and $200 million, which compares to Wall Street's $205.3 million targets.

Fair Isaac's full-year earnings view, moreover, was ratcheted down to between $1.80 and $1.90 a share on $825 million to $835 million in sales. Previously, the company had expected $2 a share on sales of $850 million.

On the flip side, internet jewelry retailer Bidz.com (BIDZ), based in California, now expects to rake in more revenue than the previously established range of $56 million to $58 million. Pretax income should likewise hover above the prior range of $5.6 million to $6 million. Analysts are looking for sales of $57.8 million and a pretax profit of $5.8 million. Shares lately added 3.1% at $10.70 in extended trading.

>To order reprints of this article, click here: Reprints